Prudential Financial’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Prudential Financial’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,369	Closed	-$3.84M	–	2716
2021 Q4	$3.84M	Buy	25,369 +3,890	+18%	+$604K	﹤0.01%	1161
2021 Q3	$3.8M	Buy	21,479 +7,153	+50%	+$1.15M	0.01%	1129
2021 Q2	$2.31M	Buy	14,326 +3,520	+33%	+$565K	﹤0.01%	1404
2021 Q1	$1.85M	Buy	10,806 +7,542	+231%	+$1.49M	﹤0.01%	1501
2020 Q4	$717K	Buy	3,264 +356	+12%	+$77K	﹤0.01%	1908
2020 Q3	$483K	Sell	2,908 -15,374	-84%	-$2.1M	﹤0.01%	1975
2020 Q2	$2.09M	Sell	18,282 -4,607	-20%	-$447K	﹤0.01%	1317
2020 Q1	$1.76M	Sell	22,889 -404	-2%	-$36.2K	﹤0.01%	1437
2019 Q4	$3M	Buy	+23,293	New	+$2.25M	﹤0.01%	1399
2019 Q3	–	Sell	-1,970	Closed	-$203K	–	2491
2019 Q2	$203K	Buy	+1,970	New	+$153K	﹤0.01%	2337

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Prudential Financial's MRTX Position: Q1 2022 in Review

Prudential Financial sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 25,369 shares — an estimated $3.84M sold.

Prudential Financial first reported a position in MRTX in Q2 2019 and held it in 10 quarters. The position peaked at $3.84M in Q4 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

Prudential Financial reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Prudential Financial sold 25,369 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $3.84M.
Prudential Financial first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
Prudential Financial's Mirati Therapeutics, Inc. Common Stock position peaked at $3.84M in Q4 2021.
253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Prudential Financial's 13F filing for Q1 2022, filed 13 May 2022.